Syntekabio Accelerates Construction of AI Supercomputing Center

[Asia Economy Reporter Hyungsoo Park] Syntekabio, an AI-based new drug development company, announced on the 14th that it will officially establish an AI Supercomputing Center.

The AI Supercomputing Center will be built on a 10,200㎡ research site in the Dungok District of Daejeon, secured in April 2020, with a total floor area of 3,954.54㎡ and a building area of 1,325.61㎡ (4 floors above ground). The goal is to complete construction within this year.

Syntekabio plans to expand its AI supercomputer infrastructure from the current scale of 3,000 units to about 10,000 units. By strengthening the infrastructure, it aims to advance its synthetic new drug candidate discovery AI platform ‘DeepMatcher’ and the cancer-specific antigen (neoantigen) prediction platform ‘NEO-ARS’. It also plans to establish a cloud service environment based on the existing platforms in a Platform as a Service (PaaS) model.

Jongseon Jeong, CEO of Syntekabio, said, "The establishment of the AI Supercomputing Center is expected to play a significant role not only in optimizing and expanding supercomputing infrastructure but also in completing the cloud service environment currently under construction."

He added, "As the AI new drug discovery platform will be expanded and provided as a cloud service, we anticipate an increase in sales following the completion of the AI Supercomputing Center."

Syntekabio’s AI Supercomputing Center will adopt a natural convection circulation outdoor air cooling design to build an energy-efficient center targeting a Power Usage Effectiveness (PUE) level of 1.1.

This content was produced with the assistance of AI translation services.